XML 48 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1

Segments (Tables)

6 Months Ended

Jun. 30, 2018

Segment information

a. Segment information:

		North America								Europe								International Markets
		Three months ended June 30,								Three months ended June 30,								Three months ended June 30,
		2018				2017				2018				2017				2018				2017
		(U.S. $ in millions)
Revenues		$	2,263			$	3,169			$	1,328			$	1,295			$	789			$	885
Gross profit			1,203				2,058				731				692				328				400
R&D expenses			182				280				73				105				25				47
S&M expenses			296				392				237				296				130				187
G&A expenses			103				144				78				89				37				45
Other income			(100	)			(8	)			(3	)			(17	)			(3	)			—
Segment profit		$	722			$	1,250			$	346			$	219			$	139			$	121
		North America								Europe								International Markets
		Six months ended June 30,								Six months ended June 30,								Six months ended June 30,
		2018				2017				2018				2017				2018				2017
		(U.S. $ in millions)
Revenues		$	4,794			$	6,409			$	2,770			$	2,636			$	1,539			$	1,603
Gross profit			2,635				4,138				1,528				1,426				641				692
R&D expenses			370				547				146				211				49				94
S&M expenses			601				833				492				575				264				345
G&A expenses			229				283				169				168				78				93
Other income			(202	)			(81	)			(2	)			(15	)			(11	)			(1	)
Segment profit		$	1,637			$	2,556			$	723			$	487			$	261			$	161

		Three months ended June 30,								Six months ended June 30,
		2018				2017				2018				2017
		(U.S. $ in millions)
North America profit		$	722			$	1,250			$	1,637			$	2,556
Europe profit			346				219				723				487
International Markets profit			139				121				261				161
Total segment profit			1,207				1,590				2,621				3,204
Profit of other activities			31				7				52				14
			1,238				1,597				2,673				3,218
Amounts not allocated to segments:
Amortization			302				411				612				731
Other asset impairments, restructuring and other items			715				419				1,422				659
Goodwill impairment			120				6,100				300				6,100
Gain (loss) on divestitures, net of divestitures related costs			10				—				(83	)			—
Inventory step-up			—				3				—				67
Other R&D expenses			—				21				22				26
Costs related to regulatory actions taken in facilities			4				15				5				49
Legal settlements and loss contingencies			20				324				(1,258	)			344
Other unallocated amounts			81				44				142				87
Consolidated operating income (loss)			(14	)			(5,740	)			1,511				(4,845	)
Financial expenses, net			236				238				507				445
Consolidated income (loss) before income taxes		$	(250	)		$	(5,978	)		$	1,004			$	(5,290	)

Schedule of Net Sales by Product Line

b. Segment revenues by major products and activities:

The following tables present revenues by major products and activities for the three and six months ended June 30, 2018 and 2017:

		Three months ended								Six months ended
		June 30,								June 30,
		2018				2017				2018				2017
		(U.S. $ in millions)
North America segment
Generic products		$	947			$	1,331			$	2,035			$	2,746
COPAXONE			464				859				940				1,656
BENDEKA / TREANDA			160				163				341				319
ProAir			115				123				245				244
QVAR			30				98				137				181
AUSTEDO			44				1				74				1
Distribution			320				275				651				570

		Three months ended								Six months ended
		June 30,								June 30,
		2018				2017				2018				2017
		(U.S. $ in millions)
Europe segment
Generic products		$	907			$	822			$	1,904			$	1,672
COPAXONE			140				138				293				290
Respiratory products			106				84				219				168

		Three months ended								Six months ended
		June 30,								June 30,
		2018				2017				2018				2017
		(U.S. $ in millions)
International Markets segment
Generic products		$	537			$	604			$	1,025			$	1,090
COPAXONE			22				26				38				47
Distribution			154				135				307				260

X

- Definition

A schedule of net sales by major product line.

+ References

No definition available.

+ Details

Name:	teva_SalesByProductLineTableTextBlock
Namespace Prefix:	teva_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration